VSIR and cancer: To date, there are two phase one clinical trials (ClinicalTrials.gov: NCT02671955, NCT04475523) analyzing safety, pharmacokinetics, and pharmacodynamics of two different anti-VISTA monoclonal antibodies in advanced cancer patients.